EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
- Author(s):
- Smolen, J.S.; Landewe, R.; Bijlsma, J.; Burmester, G.; Chatzidionysiou, K.; Dougados, M.; Nam, J.; Ramiro, S.; Voshaar, M.; Vollenhoven, R. van; Aletaha, D.; Aringer, M.; Boers, M.; Buckley, C.D.; Buttgereit, F.; Bykerk, V.; Cardiel, M.; Combe, B.; Cutolo, M.; Eijk-Hustings, Y. van; Emery, P.; Finckh, A.; Gabay, C.; Gomez-Reino, J.; Gossec, L.; Gottenberg, J.E.; Hazes, J.M.W.; Huizinga, T.; Jani, M.; Karateev, D.; Kouloumas, M.; Kvien, T.; Li, Z.G.; Mariette, X.; McInnes, I.; Mysler, E.; Nash, P.; Pavelka, K.; Poor, G.; Richez, C.; Riel, P. van; Rubbert-Roth, A.; Saag, K.; Silva, J. da; Stamm, T.; Takeuchi, T.; Westhovens, R.; Wit, M. de; Heijde, D. van der
- Published
- 2017
- Publication type
- Article / Letter to editor
- Date issued
- 2017-06-30
- Language
- English
- Is part of
- Annals of the Rheumatic Diseases (2017), Vol. 76, no. 6, p. 960-977
- hdl
- 1887/116109
- doi
- 10.1136/annrheumdis-2016-210715